Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-08-05 Major Shareholding Noti…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for Linc AB in Calliditas Therapeutics AB. It explicitly states the 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' figures for shares and voting rights, including percentages crossing a threshold (10%). This structure is characteristic of a Major Shareholding Notification, which reports changes in significant ownership levels that cross regulatory thresholds. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document length is short (4424 chars), but it is the primary notification itself, not an announcement of a report.
2024-08-05 English
Antal aktier och röster i Calliditas Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document text is a short announcement in Swedish regarding the change in the total number of outstanding shares and votes in Calliditas Therapeutics AB due to the exercise of warrants from incentive programs (ESOP 2020 and LTIP 2021). It explicitly states the new total share count and the resulting increase in share capital. This type of announcement, detailing changes in the number of shares outstanding, directly relates to capital structure changes or share issuance. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category, as the change resulted from the issuance of new shares upon warrant exercise. The document is short and appears to be a regulatory disclosure, but its core content is about a capital change.
2024-07-31 Swedish
Number of shares and votes in Calliditas Therapeutics
Share Issue/Capital Change Classification · 99% confidence The document explicitly states that the number of shares and votes has changed due to the exercise of warrants and subsequent increase in share capital. This directly relates to a change in the company's capital structure or share count. The filing is a formal announcement detailing this change. This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers announcements regarding new share issues or capital changes. It is not an earnings release (ER), a dividend notice (DIV), or a director's dealing (DIRS). Given the specific nature of the change in outstanding shares and capital, SHA is the most precise classification.
2024-07-31 English
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Earnings Release Classification · 99% confidence The document is a press release dated July 26, 2024, announcing positive topline data from the TRANSFORM Phase 2b clinical trial for the drug setanaxib in patients with primary biliary cholangitis (PBC). It details the primary endpoint results (ALP improvement), safety profile, quotes from executives and a principal investigator, and provides future clinical trial timelines. This content structure—announcing key financial or clinical results immediately upon release—is characteristic of an Earnings Release (ER) or a specific clinical trial update. Since it focuses purely on the immediate announcement of clinical trial results (not a comprehensive quarterly/annual report or a transcript), the most appropriate classification is 'Earnings Release' (ER), as these announcements often serve as the primary communication of period-specific performance highlights, even if the period is a clinical trial phase rather than a fiscal quarter. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). FY 2024
2024-07-26 English
Calliditas utläser positiva topline-data från fas 2b-studien TRANSFORM i primär gallkolangit
Earnings Release Classification · 95% confidence The document is a press release dated July 26, 2024, announcing positive topline data from a Phase 2b clinical study (TRANSFORM) for the drug setanaxib in treating primary biliary cholangitis. It details study results (ALP improvement, safety profile), includes quotes from management and a key opinion leader, and mentions future data readouts (IPF, Alport's syndrome). This content structure—announcing key clinical trial results and future expectations via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is focused purely on clinical trial results and not comprehensive quarterly financial performance (which would be an IR or 10-K), and it is an initial announcement of results, the most fitting category is Earnings Release (ER), as these often include significant operational/clinical milestones alongside or instead of pure financial figures in the biotech sector. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP). Given the focus on announcing key operational/clinical news, ER is the best fit among the provided options, although RNS is a possibility if ER is strictly interpreted as only financial earnings. FY 2024
2024-07-26 Swedish
Kommuniké från årsstämman i Calliditas Therapeutics AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kommuniké från årsstämman i Calliditas Therapeutics AB (publ)" which translates to "Communiqué from the Annual General Meeting (AGM) in Calliditas Therapeutics AB (publ)". The text details specific resolutions passed at the meeting held on June 17, 2024, including the approval of 2023 financial statements, board/auditor elections, remuneration decisions, approval of incentive programs, and authorization for share issuance/transfer. These are the core components of an AGM resolution summary. Therefore, the appropriate classification is AGM-R (AGM Information).
2024-06-17 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.